Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Accumulated Depreciation (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Accumulated Depreciation for 4 consecutive years, with $48.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 34.78% to $48.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.6 million through Dec 2025, up 34.78% year-over-year, with the annual reading at $48.6 million for FY2025, 34.78% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $48.6 million at Century Therapeutics, up from $45.6 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $48.6 million in Q4 2025, with the low at $6.5 million in Q1 2022.
  • Average Accumulated Depreciation over 4 years is $26.2 million, with a median of $24.4 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation skyrocketed 155.33% in 2023, then soared 34.78% in 2025.
  • Over 4 years, Accumulated Depreciation stood at $13.7 million in 2022, then surged by 67.25% to $22.8 million in 2023, then skyrocketed by 57.89% to $36.1 million in 2024, then skyrocketed by 34.78% to $48.6 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $48.6 million, $45.6 million, and $42.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.